Dr. Adesina discusses the important role mentors have played in her growth and development as a medical professional specializing in SCD.

Dr. Coetzer discusses a study that provides insights into the potential of new drugs to treat CML.

Dr. Becker discusses the many mutations identified in acute myeloid leukemia and the efforts of investigators to find a practical application of this information in modifying treatment.

Dr. Hoggatt looks at the therapeutic effects of blocking CD47 aside from alerting macrophages to devour tumor cells.

Dr. Garcia reviews a study that shows the importance of an accurate 4Ts assessment.

Dr. LaCasce discusses a new prognostic model in follicular lymphoma that incorporates both genetic and clinical factors.

Drs. Raje and Yee discuss two trials with elotuzumab and daratumumab that use monoclonal antibodies in the treatment of multiple myeloma.

Dr. Koury studies increase in platelet production and size due to the IL-1α-induced megakaryocyte rupture mechanism of rapid platelet production.

Dr. Raetz looks at a study that highlights the importance of the purine synthesis pathway in relapsed ALL.

Dr. Cuker studies the use of idarucizumab, a monoclonal antibody fragment, to reverse the anticoagulant effect of dabigatran in bleeding patients.

Dr. George discusses her diagnostic approach to lymphocytosis.

Drs. Oh and Fisher discuss the application of mass cytometry to analyze disease evolution in hematologic malignancies.

Dr. Quinn discusses the REACH study as part of several studies that look at hydroxyurea for the treatment of children with sickle cell anemia in sub-Saharan Africa.

Drs. Valent, Schumacher, Sörgel, Horny, and Groner talk about Paul Ehrlich's many achievements on the 100th anniversary of his death.

Dr. Williams talks about ASH's influence in the development of precision medicine, which is a big part of the new ASH Research Agenda.